Potential for serotonergic agents to treat elevated intraocular pressure and glaucoma: focus on 5-HT₂ receptor agonists

References

• Conroy DM, Acton ML. New therapies to treat sight loss in an aging population. Drug Discov. Today15, 256–259 (2010).
   PubMedGoogle Scholar
• Wostyn P, Audenaert K, De Deyn PP. Alzheimer’s disease and glaucoma: is there a causal relationship? Br. J. Ophthalmol.93, 1557–1559 (2009).
   PubMed Web of Science ®Google Scholar
• Weinreb RN, Khaw PT. Primary open angle glaucoma. Lancet363, 1711–1720 (2004).
   PubMed Web of Science ®Google Scholar
• Congdon N, O’Colmain B, Klaver CC et al. Causes and prevalence of visual impairment among adults in the United States. Arch. Ophthalmol.122, 477–485 (2004).
   PubMed Web of Science ®Google Scholar
• Resnikoff S, Pascolini D, Etya’ale D et al. Global data on visual impairment in the year 2002. Bull. World Health Organ.82, 844–851 (2004).
   PubMed Web of Science ®Google Scholar
• Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br. J. Ophthalmol.90, 262–267 (2006).
   PubMed Web of Science ®Google Scholar
• Coleman AL, Miglior S. Risk factors for glaucoma onset and progression. Surv. Ophthalmol.53, S3–S10 (2008).
   PubMed Web of Science ®Google Scholar
• Tamm ER, Fuchshofer R. What increases outflow resistance in primary open-angle glaucoma? Surv. Ophthalmol.52(Suppl. 2), S101–S104 (2007).
   PubMedGoogle Scholar
• Tamm ER. The trabecular meshwork outflow pathways: structural and functional aspects. Exp. Eye Res.88, 648–655 (2009).
   PubMed Web of Science ®Google Scholar
• Alm A, Nilsson SF. Uveoscleral outflow – a review. Exp. Eye Res.88, 760–768 (2009).
   PubMed Web of Science ®Google Scholar
• Acott TS, Kelley MJ. Extracellular matrix turnover and outflow resistance. Exp. Eye Res.86, 543–561 (2008).
   PubMed Web of Science ®Google Scholar
• Keller KE, Aga M, Bradley JM, Kelley MJ, Acott TS. Extracellular matrix turnover and outflow resistance. Exp. Eye Res.88, 676–682 (2009).
   PubMed Web of Science ®Google Scholar
• Tan JCH, Peters DM, Kaufman PL. Recent developments in understanding the pathophysiology of elevated intraocular pressure. Curr. Opin. Ophthalmol.17, 168–174 (2006).
   PubMed Web of Science ®Google Scholar
• Rhee DJ, Haddadin RI, Kang MH, Oh DJ. Matricellular proteins in the trabecular meshwork. Exp. Eye Res.88, 694–703 (2009).
   PubMed Web of Science ®Google Scholar
• Okuno T, Oku H, Sugiyama T, Ikeda T. Glutamate level in optic nerve head is increased by artificial elevation of intraocular pressure in rabbits. Exp. Eye Res.82, 465–470 (2006).
   PubMedGoogle Scholar
• Yorio T, Krishnamoorthy R, Prasanna G. Endothelin: is it a contributor to glaucoma pathophysiology? J. Glaucoma11, 259–270 (2002).
   PubMed Web of Science ®Google Scholar
• Sossi N, Anderson DR. Blockage of axonal transport in optic nerve induced by elevation of intraocular pressure. Effect of arterial hypertension induced by angiotensin I. Arch. Ophthalmol.101, 94–97 (1983).
   PubMedGoogle Scholar
• Kong GY, Van Bergen NJ, Trounce IA, Crowston JG. Mitochondrial dysfunction and glaucoma. J. Glaucoma18, 93–100 (2009).
   PubMed Web of Science ®Google Scholar
• Shifera AS, Trivedi S, Chau P, Bonnemaison LH, Iguchi R, Alvarado J. Constitutive secretion of chemokines by cultured human trabecular meshwork cells. Exp. Eye Res.91, 42–47 (2010).
   PubMed Web of Science ®Google Scholar
• Hazin R, Hendrick AM, Kahook MY. Primary open-angle glaucoma: diagnostic approaches and management. J. Natl Med. Assoc.101, 46–50 (2009).
   PubMedGoogle Scholar
• Clark AF, Yorio T. Ophthalmic drug discovery. Nat. Rev. Drug Discov.2, 448–459 (2003).
   PubMed Web of Science ®Google Scholar
• Sharif NA, Klimko P. CNS: ophthalmic Agents. In: Comprehensive Medicinal Chemistry II (Volume 6, Chapter 12). Taylor JB, Triggle DJ (Eds). Elsevier, Oxford, UK, 297–320 (2007).
   Google Scholar
• McKinnon SJ, Goldberg LD, Peeples P, Walt JG, Bramley TJ. Current management of glaucoma and the need for complete therapy. Am. J. Manag. Care14, S20–S27 (2008).
   PubMedGoogle Scholar
• Webers CA, Beckers HJ, Nuijts RM, Schouten JS. Pharmacological management of primary open-angle glaucoma: second-line options and beyond. Drugs Aging25, 729–759 (2008).
   PubMed Web of Science ®Google Scholar
• Costagliola C, dell’Omo R, Romano MR, Rinaldi M, Zeppa L, Parmeggiani F. Pharmacotherapy of intraocular pressure: part I. parasympathomimetic, sympathomimetic and sympatholytics. Expert Opin. Pharmacother.10, 2663–2677 (2009).
   PubMed Web of Science ®Google Scholar
• Costagliola C, dell’Omo R, Romano MR, Rinaldi M, Zeppa L, Parmeggiani F. Pharmacotherapy of intraocular pressure: part II. Carbonic anhydrase inhibitors, prostaglandin analogues and prostamides. Expert Opin. Pharmacother.10, 2859–2870 (2009).
   PubMed Web of Science ®Google Scholar
• Whitson JT. Glaucoma: a review of adjunctive therapy and new management strategies. Expert Opin. Pharmacother.8, 3237–3249 (2007).
   PubMed Web of Science ®Google Scholar
• Bournias TE, Lai J. Brimonidine tartrate 0.15%, dorzolamide hydrochloride 2%, and brinzolamide 1% compared as adjunctive therapy to prostaglandin analogs. Ophthalmology116, 1719–1724 (2009).
   PubMed Web of Science ®Google Scholar
• Galanopoulos A, Goldberg I. Clinical efficacy and neuroprotective effects of brimonidine in the management of glaucoma and ocular hypertension. Clin. Ophthalmol.3, 117–122 (2009).
   PubMedGoogle Scholar
• Levins LA, Peeples P. History of neuroprotection and rationale as a therapy for glaucoma. Am. J. Manag. Care14, S11–S14 (2008).
   Google Scholar
• Osborne NN. Recent clinical findings with memantine should not mean that the idea of neuroprotection in glaucoma is abandoned. Acta Ophthalmol.87, 450–454 (2009).
   PubMed Web of Science ®Google Scholar
• Ehinger B, Floren I. Retinal indolamine accumulating neurons. Neurochem. Int.1, 209–229 (1980).
   Google Scholar
• Moro F, Scapagnin U, Scaletta S, Drago F. Serotonin nerve endings in the regulation of papillary diameter. Ann. Ophthalmol.13, 487–490 (1981).
   PubMedGoogle Scholar
• Tobin AB, Unger W, Osborne NN. Evidence for presence of serotonergic nerves and receptors in the iris–ciliary body complex of the rabbit. J. Neurosci.8, 3713–3721 (1988).
   PubMed Web of Science ®Google Scholar
• Matsumoto Y, Ueda S, Kawata M. Morphological characterization and distribution of indolamine-accumulating cells in the rat retina. Acta Histochem. Cytochem.25, 45–51 (1992).
   Google Scholar
• Redburn DA, Churchill L. An indoleamine system in photoreceptor cell terminals of the Long–Evans rat retina. J. Neurosci.7, 319–329 (1987).
   PubMedGoogle Scholar
• Cooper RL, Constable IJ, Davidson L. Cathecholamines in aqueous humor of glaucoma patients. Aust. J. Ophthalmol.12, 345–349 (1984).
   PubMedGoogle Scholar
• Martin XD, Brennan MC, Lichter PR. Serotonin in human aqueous humor. Ophthalmology95, 1221–1226 (1988).
   PubMedGoogle Scholar
• Martin XD, Malina HZ, Brennan MC, Hendrickson PH, Lichter PR. The ciliary body – the third organ found to synthesize indoleamines in humans. Eur. J. Ophthalmol.2, 67–72 (1992).
   PubMedGoogle Scholar
• Trope GE, Sole M, Aedy L, Madapallimattam A. Levels of norepinephrine, epinephrine, dopamine, serotonin and N-acetylserotonin in aqueous humor. Can. J. Ophthalmol.22, 152–154 (1987).
   PubMedGoogle Scholar
• Veglio F, De Sanctis U, Schiavone D et al. Evaluation of serotonin levels in human aqueous humor. Ophthalmologica212, 160–163 (1998).
   PubMed Web of Science ®Google Scholar
• Boerrigter RM, Sietsema JV, Kema IP. Serotonin (5-HT) and the rat’s eye. Some pilot studies. Doc. Ophthalmol.82, 141–150 (1992).
   PubMed Web of Science ®Google Scholar
• Pootanakit K, Brunken WJ. 5-HT1A and 5-HT7 receptor expression in the mammalian retina. Brain Res.875, 152–156 (2002).
   Google Scholar
• Pootanakit K, Prior KJ, Hunter DJ, Brunken WJ. 5-HT2A receptors in the rabbit retina: potential presynaptic modulators. Vis. Neurosci.16, 221–230 (1999).
   PubMedGoogle Scholar
• Nash M, Flanigan T, Leslie R, Osborne NN. Serotonin-2A receptor mRNA expression in rat retinal pigment epithelial cells. Ophthalmic Res.31, 1–4 (1993).
   Google Scholar
• Turner HC, Alvarez LJ, Candia OA, Bernstein AM. Characterization of serotonergic receptors in rabbit, porcine and human conjunctivae. Curr. Eye Res.27, 205–215 (2003).
   PubMed Web of Science ®Google Scholar
• Chidlow G, Le Corre, Osborne NN. Localization of 5-hydroxytryptamine-1A and 5-hydroxytryptamine-7 receptors in rabbit ocular and brain tissues. Neuroscience87, 675–689 (1998).
   PubMed Web of Science ®Google Scholar
• Chidlow G, Hiscott PS, Osborne NN. Expression of serotonin receptor mRNAs in human ciliary body: a polymerase chain reaction study. Graefe’s Arch. Clin. Exp. Ophthalmol.242, 259–264 (2004).
   PubMedGoogle Scholar
• Sharif NA, Senchyna M. Serotonin receptor subtype mRNA expression in human ocular tissues determined by RT-PCR. Mol. Vis.12, 1040–1047 (2006).
   PubMed Web of Science ®Google Scholar
• Mallorga P, Sugrue MF. Characterization of serotonin receptors in the iris–ciliary body of the albino rabbit. Curr. Eye Res.6, 527–532 (1987).
   PubMed Web of Science ®Google Scholar
• Sharif NA, Kelly CR, Crider JY, Senchyna M. RT-PCR mapping of serotonin receptor subtype mRNAs in human ciliary body and trabecular meshwork. Assoc. Res. Vis. Ophthalmol. Abst.3688 (2005).
   Google Scholar
• Chidlow G, DeSantis LM, Sharif NA, Osborne NN. Characteristics of [3H]-5-hydroxytryptamine binding to iris–ciliary body tissue of the rabbit. Invest. Ophthalmol. Vis. Sci.36, 2238–2245 (1995).
   PubMedGoogle Scholar
• Sharif NA, Kelly CR, Crider JY, Davis TL. Serotonin-2 (5-HT2) receptor-mediated signal transduction in human ciliary muscle cells: role in ocular hypotension. J. Ocul. Pharmacol. Ther.22, 389–401 (2006).
   PubMedGoogle Scholar
• Neufeld AH, Ledgard SE, Jumblatt MM, Klyce SD. Serotonin-stimulated cyclic AMP synthesis in the rabbit corneal epithelium. Invest. Ophthalmol. Vis. Sci.23, 193–198 (1982).
   PubMed Web of Science ®Google Scholar
• Blazynski C, Ferrendelli JA, Cohen AI. Indolamine-sensitive adenylate cyclase in rabbit retina: characterization and distribution. J. Neurochem.45, 440–447 (1985).
   PubMedGoogle Scholar
• Akhtar RA. Effects of norepinephrine and 5-hydroxytryptamine on phosphoinositide-PO4 turnover in rabbit cornea. Exp. Eye Res.44, 849–862 (1987).
   PubMed Web of Science ®Google Scholar
• Cutcliffe N, Osborne NN. Serotonergic and cholinergic stimulation of inositol phosphate formation in the rabbit retina. Evidence for the presence of serotonin and muscarinic receptors. Brain Res.421, 95–104 (1987).
   PubMedGoogle Scholar
• Barnett NL, Osborne NN. The presence of serotonin (5-HT1) receptor negatively coupled to adenylate cyclase in rabbit and human iris–ciliary process. Exp. Eye Res.57, 209–216 (1993).
   PubMed Web of Science ®Google Scholar
• Tobin AB, Osborne NN. Evidence for the presence of serotonin receptors negatively coupled to adenylate cyclase in the rabbit iris–ciliary body. J. Neurochem.53, 686–691 (1989).
   PubMedGoogle Scholar
• Osborne NN, Ghazi H. 5-HT1A receptors positively coupled to cAMP formation in the rabbit retina. Neurochem. Int.19, 407–511 (1991).
   Web of Science ®Google Scholar
• Osborne NN, Fitzgibbon F, Nash M, Liu NP, Leslie R, Cholewinski A. Serotonergic, 5-HT2, receptor-mediated phosphoinositide turnover and mobilization of calcium in cultured rat retinal pigment epithelium cells. Vis. Res.33, 2171–2179 (1993).
   PubMedGoogle Scholar
• Crider JY, Williams GW, Drace CD, Katoli P, Senchyna M, Sharif NA. Pharmacological characterization of a serotonin receptor (5-HT7) stimulating cAMP production in human corneal epithelial cells. Invest. Ophthalmol. Vis. Sci.44, 4837–4844 (2003).
   PubMed Web of Science ®Google Scholar
• Inoue-Matsuhisa E, Moroi SE, Takenaka H, Sogo S, Mano T. 5-HT2 receptor-mediated phosphoinositide hydrolysis in bovine ciliary epithelium. J. Ocular Pharmacol. Ther.19, 55–62 (2003).
   PubMedGoogle Scholar
• Sharif NA, Kelly C, McLaughlin MA. Human trabecular meshwork cells express functional serotonin-2A (5-HT2A) receptors: role in IOP reduction. Invest. Ophthalmol. Vis. Sci.47, 4001–4010 (2006).
   PubMedGoogle Scholar
• Harris LC, Awe SO, Opere CA, Leday AM, Ohia SE, Sharif NA. [3H]Serotonin release from bovine iris–ciliary body: pharmacology of pre-junctional serotonin (5-HT7) autoreceptors. Exp. Eye Res.73, 59–67 (2001).
   PubMed Web of Science ®Google Scholar
• Harris LC, Awe SO, Opere CA, LeDay AM, Ohia SE, Sharif NA. Pharmacology of serotonin receptors modulating electrically-induced [3H]norepinephrine release from isolated mammalian iris–ciliary bodies. J. Ocul. Pharmacol. Ther.18, 339–348 (2002).
   PubMedGoogle Scholar
• Lograno MS, Romano MR. Pharmacological characterization of the 5-HT1A, 5-HT2 and 5-HT3 receptors in the bovine ciliary muscle. Eur. J. Pharmacol.464, 69–74 (2003).
   PubMedGoogle Scholar
• Mangel SS, Brunken WJ. The effects of serotonin drugs on horizontal and ganglion cells in the rabbit retina. Vis. Neurosci.8, 213–218 (1992).
   PubMedGoogle Scholar
• Brunken WJ, Jin XT, Pis-Lopez AM. The properties of the serotonergic system in the retina. Prog. Ret. Res.16, 75–99 (1993).
   Google Scholar
• Brunken WJ, Jin XT. A role for 5-HT3 receptors in visual processing in the mammalian retina. Vis. Neurosci.10, 511–522 (1993).
   PubMedGoogle Scholar
• Brunken WJ, Daw NW. The effects of serotonin agonists and antagonists on the response properties of complex ganglion cells of the rabbit retina. Vis. Neurosci.1, 181–188 (1988).
   PubMedGoogle Scholar
• Klyce SD, Palkama KA, Harkone M et al. Neural serotonin stimulates chloride transport in the rabbit corneal epithelium. Invest. Ophthalmol. Vis. Sci.23, 181–192 (1982).
   PubMed Web of Science ®Google Scholar
• Chiang TS. Effects of intravenous infusions of histamine, 5-hydroxytryptamine, bradykinin and prostaglandins on intraocular pressure. Arch. Int. Pharmacodyn. Ther.207, 131–138 (1974).
   PubMedGoogle Scholar
• Costagliola C, Parmeggiani F, Sebastiani A. SSRIs and intraocular pressure modifications: evidence, therapeutic implications and possible mechanisms. CNS Drugs18, 475–484 (2004).
   PubMed Web of Science ®Google Scholar
• Krootila K, Palkama A, Uusitalo H. Effects of serotonin and its antagonist (ketanserin) on intraocular pressure in the rabbit. J. Ocul. Pharmacol.3, 279–290 (1987).
   PubMedGoogle Scholar
• Meyer-Bothling U, Bron AJ, Osborne NN. Topical application of serotonin or the 5-HT1-agonist 5-CT on intraocular pressure in rabbits. Invest. Ophthalmol. Vis. Sci.34, 3035–3042 (1993).
   PubMed Web of Science ®Google Scholar
• Chu TC, Ogidigben MJ, Potter DE. 8-OH-DPAT-induced ocular hypotension: sites and mechanisms of action. Exp. Eye Res.69, 227–238 (1999).
   PubMedGoogle Scholar
• Chidlow G, Nash MS, DeSantis L, Osborne NN. The 5-HT1A receptor agonist 8-OH-DPAT lowers intraocular pressure in normotensive NZW rabbits. Exp. Eye Res.69, 587–593 (1999).
   PubMed Web of Science ®Google Scholar
• Chidlow G, Cupido A, Melena J, Osborne NN. Flesinoxan, a 5-HT1A receptor agonist/5-HT1-adrenoceptor antagonist, lowers intraocular pressure in NZW rabbits. Curr. Eye Res.23, 144–153 (2001).
   PubMed Web of Science ®Google Scholar
• May JA, McLaughlin MA, Sharif NA, Hellberg MR, Dean TR. Evaluation of the ocular hypotensive response of serotonin 5-HT1A and 5-HT2 receptor ligands in conscious ocular hypertensive cynomolgus monkeys. J. Pharmacol. Exp. Ther.306, 301–309 (2003).
   PubMed Web of Science ®Google Scholar
• Chang FW, Burke JA, Potter DE. Mechanism of ocular hypotensive action of ketanserin. J. Ocular Pharmacol.1, 137–147 (1985).
   PubMedGoogle Scholar
• Chiou GC, Li BH. Ocular hypotensive actions of serotonin antagonist-ketanserin and analogs. J. Ocular Pharmacol. Ther.8, 11–21 (1992).
   Google Scholar
• Costagliola C, Iuliano G, Rinaldi M, Russo V, Scibelli G, Mastropasqua L. Effect of topical ketanserin administration on intraocular pressure. Br. J. Pharmacol.77, 344–348 (1993).
   Google Scholar
• Mastropasqua L, Costagliola C, Ciancaglini M, Carpineto P, Gallenga PE. Ocular hypotensive effect of ketanserin in patients with primary open angle glaucoma. Acta. Ophthalmol. Scand. Suppl.224, 24–25 (1997).
   Google Scholar
• Takat D, Guler C, Arici M, Topalkara A, Erdogan H. Effect of ketanserin administration on intraocular pressure. Ophthalmologica215, 419–423 (2001).
   PubMedGoogle Scholar
• Takenaka H, Mano T, Maeno T, Okada M, Okano Y, Mitsuka M. The effect of anplag (sarpogrelate HCl), novel selective 5-HT2 antagonist on intraocular pressure in glaucoma patients. Invest. Ophthalmol. Vis. Sci.36, S734 (1995).
   Google Scholar
• Cernerud M, Lundstrom H, Nilsson BM, Thor M. Amino-substituted 1H-pyrazin-2-ones and 1H-quinoxalin-2-ones. US Patent 7244722 (2007).
   Google Scholar
• Berthold M, Crossley, R, Ward T. Imidazo[1,5-a]pyridine or imidazo[1,5-a]piperidine derivatives and their use for the preparation of medicaments against 5-HT2A receptor-related disorders. World Patent 2005/021545 A1 (2005).
   Google Scholar
• Hoyer D, Clarke DE, Fozard JR et al. VII. International union of pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharm. Rev.46, 157–203 (1994).
   PubMed Web of Science ®Google Scholar
• Hoyer D, Hannon JP, Martin GR. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol. Biochem. Behav.71, 533–554 (2002).
   PubMed Web of Science ®Google Scholar
• Oshika T, Araie A, Sugiyama T, Nakajima M, Azuma I. Effect of bunazosin hydrochloride on intraocular pressure and aqueous humor dynamics in normotensive human eyes. Arch. Ophthalmol.109, 1569–1574 (1991).
   PubMed Web of Science ®Google Scholar
• Wang RF, Lee PY, Mittag TW, Podos SM, Serle JB. Effect of 5-methyl-urapidil, an α-1a-adrenergic antagonist and 5-hydroxytrptamine-1A agonist, on aqueous humor dynamics in monkeys and rabbits. Curr. Eye Res.16, 769–775 (1997).
   PubMed Web of Science ®Google Scholar
• Yoshio R, Taniguchi T, Itoh H, Muramatsu I. Affinity of serotonin receptor antagonists and agonists to recombinant and native α1-adrenoceptor subtypes. Jpn J. Pharmacol.86, 189–195 (2001).
   PubMedGoogle Scholar
• Sharif NA, McLaughlin MA, Kelly CR. AL-34662: a potent, selective and efficacious ocular hypotensive serotonin-2 receptor agonist. J. Ocular Pharmacol. Ther.23, 1–13 (2007).
   PubMed Web of Science ®Google Scholar
• May JA, Dantanarayana AP, Zinke PW, McLaughlin MA, Sharif NA. 1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity. J. Med. Chem.49, 318–328 (2006).
   PubMed Web of Science ®Google Scholar
• May JM, Chen H-H, Rusinko A, Lynch VM, Sharif NA, McLaughlin MA. A novel and selective 5-HT2 receptor agonist with ocular hypotensive activity: (S)-(+)-1-(2-aminopropyl)-8,9-dihydropyrano-[3,2-e]indole. J. Med. Chem.46, 4188–4195 (2003).
   PubMedGoogle Scholar
• Sharif NA, McLaughlin, MA, Kelly CR et al. Cabergoline: pharmacology, ocular hypotensive studies in multiple species, and aqueous humor dynamic modulation in cynomolgus monkey eyes. Exp. Eye Res.88, 386–397 (2006).
   Google Scholar
• May JA, Dean TR, Sharif NA, Hellberg MR. Serotonergic 5-HT2 agonists for treating glaucoma. US Patent 6664286 B1 (2003).
   Google Scholar
• Gabelt BT, Okka M, Dean TR, Kaufman PL. Aqueous humor dynamics in monkeys after topical R-DOI. Invest. Ophthalmol. Vis. Sci.46, 4691–4696 (2005).
   PubMedGoogle Scholar
• Kehne JH, Baron BM, Carr AA et al. Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile. J. Pharmacol. Exp. Ther.277, 968–981 (1996).
   PubMed Web of Science ®Google Scholar
• Wainscott DB, Lucaites VL, Kursar JD, Baez M, Nelson DL. Pharmacologic characterization of the human 5-hydroxytryptamine2B receptor: evidence for species differences. J. Pharmacol. Exp. Ther.276, 720–726 (1996).
   PubMedGoogle Scholar
• Kennett GA, Wood MD, Bright F et al. SB 242084, a selective and brain penetrant 5-HT2C receptor antagonist. Neuropharmacology36, 609–620 (1997).
   PubMed Web of Science ®Google Scholar
• Wood MD, Thomas DR, Gager TL et al. Pharmacological characterisation of the human 5-HT2B and 5-HT2C receptors in functional studies. Pharmacol. Rev. Commun.9, 259–268 (1997).
   Google Scholar
• Porter RHP, Benwell KR, Lamb H et al. Functional characterization of agonists at recombinant human 5-HT2A, 5-HT2B and 5-HT2C receptors in CHO-K1 cells. Brit. J. Pharmacol.128, 13–20 (1999).
   PubMed Web of Science ®Google Scholar
• Jerman JC, Brough SJ, Gager T et al. Pharmacological characterization of human 5-HT2 receptor subtypes. Eur. J. Pharmacol.414, 23–30 (2001).
   PubMed Web of Science ®Google Scholar
• Weinreb RN, Kashiwagi K, Kashiwagi F et al. Prostaglandins increase matrix metalloproteinase release from human ciliary smooth muscle cells. Invest. Ophthalmol. Vis. Sci.38, 2772–2780 (1997).
   PubMed Web of Science ®Google Scholar
• Wiederholt M, Thieme H, Stumpff F. The regulation of trabecular meshwork and ciliary muscle contractility. Prog. Retinal Eye Res.19, 271–295 (2000).
   PubMed Web of Science ®Google Scholar
• WuDunn D. Mechanobiology of trabecular meshwork cells. Exp. Eye Res.88, 718–723 (2009).
   PubMed Web of Science ®Google Scholar
• Hellberg MR, McLaughlin MA, Sharif NA et al. Identification and characterization of the ocular hypotensive efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist, and AL-6598, a DP prostaglandin receptor agonist. Surv. Ophthalmol.47(Suppl. 1), S13–S33 (2002).
   PubMed Web of Science ®Google Scholar
• Sharif NA, Xu SX, Crider JY, McLaughlin M, Davis TL. Levobetaxolol (Betaxon™) and other β-adrenergic antagonists: preclinical pharmacology, IOP-lowering activity and sites of action in human eyes. J. Ocular Pharmacol. Ther.17, 305–317 (2001).
   PubMed Web of Science ®Google Scholar
• Toris CB, Zhan GL, Camras CB, McLaughlin MA. Effects of travoprost on aqueous humor dynamics in monkeys. J. Glaucoma14, 70–73 (2005).
   PubMed Web of Science ®Google Scholar
• Regina MJ, Winter JC, Rabin RA. Characterization of a novel effect of serotonin 5-HT1A and 5-HT2A receptors: increasing cGMP levels in rat frontal cortex. Neuropharmacology45, 1041–1049 (2003).
   PubMedGoogle Scholar
• Dismuke WM, Mbadugha CC, Ellis DZ. NO-induced regulation of human trabecular meshwork cell volume and aqueous humor outflow facility involve the BKCa ion channel. Am. J. Physiol. Cell Physiol.294, C1378–C1386 (2008).
   PubMed Web of Science ®Google Scholar
• Dismuke WM, Sharif NA, Ellis DZ. Human trabecular meshwork cell volume decrease by NO-independent soluble guanylate cyclase activators YC-1 and BAY-58–2667 involves the BKCa ion channel. Invest. Ophthalmol. Vis. Sci.50, 3353–3359 (2009).
   PubMedGoogle Scholar
• Toris CB, Zhan GL, McLaughlin MA. Effects of brinzolamide on aqueous humor dynamics in monkeys and rabbits. J. Ocular Pharmacol. Ther.19, 397–404 (2003).
   PubMedGoogle Scholar
• Sharif NA, Williams GW, Crider JY, Xu SX, Davis TL. Molecular pharmacology of the ocular hypotensive DP/EP2 class prostaglandin AL-6598 and localization of DP and EP2 receptor sites in human eyes. J. Ocular Pharmacol. Ther.20, 489–508 (2004).
   PubMed Web of Science ®Google Scholar
• Toris CB, Zhan GL, Feilmeier MR, Camras CB, McLaughlin MA. Effects of a prostaglandin DP receptor agonist, AL-6598, on aqueous humor dynamics in a nonhuman primate model of glaucoma. J. Ocul. Pharmacol. Ther.22, 86–92 (2006).
   PubMed Web of Science ®Google Scholar
• Selliah RD, Hellberg MR, Sharif NA et al. AL-12182, a novel 11-oxa prostaglandin analog with topical ocular hypotensive activity in the monkey. Bioorgan. Med. Chem. Lett.14, 4525–4528 (2004).
   PubMedGoogle Scholar
• Sharif NA, McLaughlin MA, Kelly CR, Xu SX, Crider JY, Parker J. Preclinical pharmacology of AL-12182, a new ocular hypotensive 11-oxa-prostaglandin analog. J. Ocular Pharmacol. Ther.22, 291–309 (2006).
   PubMedGoogle Scholar
• May JA, Dean TR, Sharif NA, Chen H-W. Serotonergic 5-HT7 receptor compounds for treating ocular and CNS disorders. US Patent 7060704 (2006).
   Google Scholar
• Evans DW, Hosking SL, Gherghel D, Bartlett JD. Contrast sensitivity improves after brimonidine therapy in primary open-angle glaucoma: a case for neuroprotection. Br. J. Ophthalmol.87, 1463–1465 (2003).
   PubMedGoogle Scholar
• Croxtall JD, Scott LJ. Brinzolamide/timolol: in open-angle glaucoma and ocular hypertension. Drugs Aging26, 437–446 (2009).
   PubMedGoogle Scholar
• Ferrer E. Trabecular meshwork as a new target for the treatment of glaucoma. Drug News Perspect.19, 151–158 (2006).
   PubMedGoogle Scholar
• Dalhmann-Noor AH, Vijay S, Strid Limb G, Khaw PT. Strategies for optic nerve rescue and regeneration in glaucoma and optic neuropathies. Drug Discov. Today15, 287–299 (2010).
   PubMedGoogle Scholar
• Cho KS, Chen DF. Promoting optic nerve regeneration in adult mice with a pharmaceutical approach. Neurochem. Res.33, 2126–2133 (2008).
   PubMed Web of Science ®Google Scholar
• Charalambous P, Hurst LA, Thanos S. Engrafted chicken neural tube-derived stem cells support the innate propensity for axonal regeneration within the rat optic nerve. Invest. Ophthalmol. Vis. Sci.49, 3513–3524 (2008).
   PubMed Web of Science ®Google Scholar
• Osborne NN, Cazevielle C, Carvalho AL et al.In vivo and in vitro experiments show that betaxolol is a retinal neuroprotective agent. Brain Res.751, 113–123 (1997).
   PubMed Web of Science ®Google Scholar
• Agarwal N, Krishnamoorthy RR, Landers R et al. Levobetaxolol-induced up-regulation of retinal bFGF and CNTF mRNAs and preservation of retinal function against a photic-induced retinopathy. Exp. Eye Res.74, 445–453 (2002).
   PubMed Web of Science ®Google Scholar
• Nagata T, Ueno S, Morita H et al. Direct inhibition of N-methyl-D-aspartate (NMDA)-receptor function by antiglaucomatous β-antagonists. J. Pharmacol. Sci.106, 423–434 (2008).
   PubMed Web of Science ®Google Scholar
• Mackenzie P, Cioffi G. How does lowering of intraocular pressure protect the optic nerve? Surv. Ophthalmol.53(Suppl. 1), S39–S43 (2008).
   Google Scholar
• Smith PD, Sun F, Park KK et al. SOCS3 deletion promotes optic nerve regeneration. Neuron64, 617–623 (2009).
   PubMed Web of Science ®Google Scholar
• Takayama Y, Yukuo Y, Masayoshi U. Visual function disorder improving agents. US Patent 7109208 (2006).
   Google Scholar
• Azuma M, Yoshida Y, Waki M, Uehata M. Agents for prophylaxis and treatment of glaucoma. US Patent 6649625 (2003).
   Google Scholar
• Osborne NN. Mitochondria: their role in ganglion cell death and survival in primary open angle glaucoma. Exp. Eye Res.90, 750–757 (2010).
   PubMed Web of Science ®Google Scholar